scispace - formally typeset
Search or ask a question
Institution

Katholieke Universiteit Leuven

EducationLeuven, Belgium
About: Katholieke Universiteit Leuven is a education organization based out in Leuven, Belgium. It is known for research contribution in the topics: Population & Transplantation. The organization has 61109 authors who have published 176584 publications receiving 6210872 citations.


Papers
More filters
Journal ArticleDOI
Eric Pujade-Lauraine1, Jonathan A. Ledermann2, Frédéric Selle, Val Gebski3, Richard T Penson4, Amit M. Oza5, Jacob Korach6, Tomasz Huzarski7, Andres Poveda, Sandro Pignata, Michael Friedlander8, Nicoletta Colombo9, Philipp Harter, Keiichi Fujiwara10, Isabelle Ray-Coquard11, Susana Banerjee12, Joyce F. Liu4, Elizabeth S. Lowe13, Ralph Bloomfield13, Patricia Pautier14, Tomasz Byrski15, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R Clamp, Richard T. Penson4, Amit M. Oza5, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya16, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann2, Sarah Williams, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe S. Sonke17, Florence Joly, Anne Floquet, H. Hirte, Amnon Amit, Tjoung-Won Park-Simon18, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim19, Jae Hoon Kim20, Laurence Gladieff, Roberto Sabbatini, David M. O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid A. Boere, Petronella B. Ottevanger, Joo-Hyun Nam, Elias Abdo Filho21, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan E Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim19, Jae Weon Kim20, Roberto Hegg, Ignace Vergote15 
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Abstract: Summary Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2 ) mutation using a tablet formulation of olaparib. Methods This international, multicentre, double-blind, randomised, placebo-controlled, phase 3 trial evaluated olaparib tablet maintenance treatment in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received at least two lines of previous chemotherapy. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status at baseline of 0–1 and histologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometrioid cancer, including primary peritoneal or fallopian tube cancer. Patients were randomly assigned 2:1 to olaparib (300 mg in two 150 mg tablets, twice daily) or matching placebo tablets using an interactive voice and web response system. Randomisation was stratified by response to previous platinum chemotherapy (complete vs partial) and length of platinum-free interval (6–12 months vs ≥12 months) and treatment assignment was masked for patients, those giving the interventions, data collectors, and data analysers. The primary endpoint was investigator-assessed progression-free survival and we report the primary analysis from this ongoing study. The efficacy analyses were done on the intention-to-treat population; safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01874353, and is ongoing and no longer recruiting patients. Findings Between Sept 3, 2013, and Nov 21, 2014, we enrolled 295 eligible patients who were randomly assigned to receive olaparib (n=196) or placebo (n=99). One patient in the olaparib group was randomised in error and did not receive study treatment. Investigator-assessed median progression-free survival was significantly longer with olaparib (19·1 months [95% CI 16·3–25·7]) than with placebo (5·5 months [5·2–5·8]; hazard ratio [HR] 0·30 [95% CI 0·22–0·41], p vs two [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten [5%] vs four [4%]). Serious adverse events were experienced by 35 (18%) patients in the olaparib group and eight (8%) patients in the placebo group. The most common in the olaparib group were anaemia (seven [4%] patients), abdominal pain (three [2%] patients), and intestinal obstruction (three [2%] patients). The most common in the placebo group were constipation (two [2%] patients) and intestinal obstruction (two [2%] patients). One (1%) patient in the olaparib group had a treatment-related adverse event (acute myeloid leukaemia) with an outcome of death. Interpretation Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Apart from anaemia, toxicities with olaparib were low grade and manageable. Funding AstraZeneca.

1,280 citations

Journal ArticleDOI
23 Aug 2007-Nature
TL;DR: These studies uncover surprisingly pivotal roles of KIN10/11 in linking stress, sugar and developmental signals to globally regulate plant metabolism, energy balance, growth and survival.
Abstract: Photosynthetic plants are the principal solar energy converter sustaining life on Earth. Despite its fundamental importance, little is known about how plants sense and adapt to darkness in the daily light-dark cycle, or how they adapt to unpredictable environmental stresses that compromise photosynthesis and respiration and deplete energy supplies. Current models emphasize diverse stress perception and signalling mechanisms. Using a combination of cellular and systems screens, we show here that the evolutionarily conserved Arabidopsis thaliana protein kinases, KIN10 and KIN11 (also known as AKIN10/At3g01090 and AKIN11/At3g29160, respectively), control convergent reprogramming of transcription in response to seemingly unrelated darkness, sugar and stress conditions. Sensing and signalling deprivation of sugar and energy, KIN10 targets a remarkably broad array of genes that orchestrate transcription networks, promote catabolism and suppress anabolism. Specific bZIP transcription factors partially mediate primary KIN10 signalling. Transgenic KIN10 overexpression confers enhanced starvation tolerance and lifespan extension, and alters architecture and developmental transitions. Significantly, double kin10 kin11 deficiency abrogates the transcriptional switch in darkness and stress signalling, and impairs starch mobilization at night and growth. These studies uncover surprisingly pivotal roles of KIN10/11 in linking stress, sugar and developmental signals to globally regulate plant metabolism, energy balance, growth and survival. In contrast to the prevailing view that sucrose activates plant SnRK1s (Snf1-related protein kinases), our functional analyses of Arabidopsis KIN10/11 provide compelling evidence that SnRK1s are inactivated by sugars and share central roles with the orthologous yeast Snf1 and mammalian AMPK in energy signalling.

1,278 citations

Journal ArticleDOI
TL;DR: Radical nephrectomy done before interferon-alfa-based immunotherapy might substantially delay time to progression and improve survival of patients with metastatic renal cell carcinoma who present with good performance status.

1,277 citations

Proceedings ArticleDOI
01 Dec 2013
TL;DR: This paper proposes fast super-resolution methods while making no compromise on quality, and supports the use of sparse learned dictionaries in combination with neighbor embedding methods, and proposes the anchored neighborhood regression.
Abstract: Recently there have been significant advances in image up scaling or image super-resolution based on a dictionary of low and high resolution exemplars. The running time of the methods is often ignored despite the fact that it is a critical factor for real applications. This paper proposes fast super-resolution methods while making no compromise on quality. First, we support the use of sparse learned dictionaries in combination with neighbor embedding methods. In this case, the nearest neighbors are computed using the correlation with the dictionary atoms rather than the Euclidean distance. Moreover, we show that most of the current approaches reach top performance for the right parameters. Second, we show that using global collaborative coding has considerable speed advantages, reducing the super-resolution mapping to a precomputed projective matrix. Third, we propose the anchored neighborhood regression. That is to anchor the neighborhood embedding of a low resolution patch to the nearest atom in the dictionary and to precompute the corresponding embedding matrix. These proposals are contrasted with current state-of-the-art methods on standard images. We obtain similar or improved quality and one or two orders of magnitude speed improvements.

1,276 citations

Journal ArticleDOI
29 Apr 2016-Science
TL;DR: Deep sequencing of the gut microbiomes of 1135 participants from a Dutch population-based cohort shows relations between the microbiome and 126 exogenous and intrinsic host factors, including 31 intrinsic factors, 12 diseases, 19 drug groups, 4 smoking categories, and 60 dietary factors, and an important step toward a better understanding of environment-diet-microbe-host interactions.
Abstract: Deep sequencing of the gut microbiomes of 1135 participants from a Dutch population-based cohort shows relations between the microbiome and 126 exogenous and intrinsic host factors, including 31 intrinsic factors, 12 diseases, 19 drug groups, 4 smoking categories, and 60 dietary factors. These factors collectively explain 18.7% of the variation seen in the interindividual distance of microbial composition. We could associate 110 factors to 125 species and observed that fecal chromogranin A (CgA), a protein secreted by enteroendocrine cells, was exclusively associated with 61 microbial species whose abundance collectively accounted for 53% of microbial composition. Low CgA concentrations were seen in individuals with a more diverse microbiome. These results are an important step toward a better understanding of environment-diet-microbe-host interactions.

1,272 citations


Authors

Showing all 61602 results

NameH-indexPapersCitations
Eugene Braunwald2301711264576
Joseph L. Goldstein207556149527
Rakesh K. Jain2001467177727
Stefan Schreiber1781233138528
Masayuki Yamamoto1711576123028
Jun Wang1661093141621
David R. Jacobs1651262113892
Klaus Müllen1642125140748
Peter Carmeliet164844122918
Hua Zhang1631503116769
William J. Sandborn1621317108564
Elliott M. Antman161716179462
Tobin J. Marks1591621111604
Ian A. Wilson15897198221
Johan Auwerx15865395779
Network Information
Related Institutions (5)
University of Minnesota
257.9K papers, 11.9M citations

94% related

University of Toronto
294.9K papers, 13.5M citations

93% related

University of California, San Diego
204.5K papers, 12.3M citations

93% related

Stanford University
320.3K papers, 21.8M citations

93% related

McGill University
162.5K papers, 6.9M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023307
2022857
202111,007
202010,541
20199,719
20189,532